## **Core Concept**
Pulmonary vasodilatation refers to the widening of blood vessels in the lungs, which decreases pulmonary vascular resistance and pressure. This process is crucial in managing conditions like pulmonary hypertension. Various pharmacological agents can cause pulmonary vasodilatation by acting on different receptors or pathways.

## **Why the Correct Answer is Right**
Prostaglandin I2 (PGI2), also known as **prostacyclin**, is a potent vasodilator that causes pulmonary vasodilatation. It works by stimulating the **adenylate cyclase** pathway, increasing cyclic AMP (cAMP) levels within smooth muscle cells, leading to relaxation and vasodilation. This mechanism is particularly beneficial in treating pulmonary arterial hypertension.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While certain prostaglandins like PGE1 can cause vasodilation, they are not as specifically known for pulmonary vasodilatation as prostacyclin (PGI2).
- **Option B:** This option is blank and does not provide a valid choice for consideration.
- **Option D:** Similarly, this option is blank and does not offer a viable alternative.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **prostacyclin analogs**, such as **epoprostenol**, are used in the treatment of **pulmonary arterial hypertension**. These drugs mimic the effect of natural prostacyclin, promoting pulmonary vasodilatation and improving symptoms and exercise capacity in patients.

## **Correct Answer:** C. Prostaglandin I2 (prostacyclin).